Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: MDD, Depression
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma
Interventions: Dendritic Cells Vaccine, Lysate of Tumor, Gemcitabine, Imiquimod, Leukapheresis; Biological · Drug · Procedure
Lead sponsor: Macarena De La Fuente, MD; Other
Eligibility: 1 Year to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sleep Wake Disorders, Circadian Rhythm Disorders
Interventions: Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C), Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C); Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Concord, California • Fairfield, California • Goleta, California + 7 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Fort Lauderdale, Florida • Miami, Florida + 4 more

Conditions: HIV Infections
Interventions: GSK3640254, DTG, GSK3640254/DTG; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: EVG, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee

Conditions: Phenylketonuria, Healthy
Interventions: SYNB1618, Placebo; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Hidradenitis Suppurativa
Interventions: Bermekimab, Adalimumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole, Dexpramipexole Placebo; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Congenital Heart Disease in Children, Hypoxia, Neurodevelopmental Disorders, Complex Congenital Heart Disease
Interventions: Single Arm, Neonatal Neurobehavioral Scale; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 0 Years to 52 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • Scarborough, Maine + 1 more

Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Selinexor; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Alopecia
Interventions: Fraxel Dual laser, Halo laser; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Prostate Cancer Metastatic
Interventions: ADI-212, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: Healthy Aging
Interventions: Go4Life-Physical Activity/Exercise Program "Workout to Go" 5, ActuaYa Educational Sessions; Other · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19 Vaccination
Interventions: CONFIDENCE; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Small Cell Lung Cancer
Interventions: Trilaciclib, Placebo, Topotecan; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 35
States / cities: Hot Springs, Arkansas • Rogers, Arkansas • Corona, California + 28 more

Conditions: Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
Interventions: Pomalidomide, Nivolumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMT-162; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more

Conditions: HIV
Interventions: N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus), N332-GT5 gp140 (SC, Fractioned), SMNP (IM, Bolus), SMNP (IM, Fractioned), SMNP (SC, Bolus), SMNP (SC, Fractioned); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more

Conditions: Hydration Status, Substrate Metabolism During Exercise
Interventions: Part 1 - Exercise Trial, Part 1 - Experimental Trial, Part 2 - Oral Glucose Tolerance Test; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Healthy
Interventions: LY2409021; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Cancer Of Prostate, Prostate Neoplasms
Interventions: PDS01ADC, Docetaxel, M7824, Prednisone, ADT; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Implementing and Sustaining a Sleep Treatment to Improve Community Mental Health Part 3: Sustainment

Linkage to Care - Part I

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

Dexpramipexole SAD/MAD Study

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Fractional Photothermolysis for Hair Follicle Induction

A Phase 1/2 Trial of ADI-212 in mCRPC

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Preventing Chronic Disease: ActuaYa

A Multicomponent Clinic-based Intervention to Promote COVID-19 Vaccine Intention and Uptake Among Diverse Youth and Adolescents

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

The Effect of Hydration Status on Substrate Oxidation at Rest and During Light and Moderate Exercise

A Study of LY2409021 Formulations in Healthy Participants

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer